blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3494138

EP3494138 - COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.09.2022
Database last updated on 03.09.2024
FormerExamination is in progress
Status updated on  15.04.2020
FormerRequest for examination was made
Status updated on  10.05.2019
FormerThe international publication has been made
Status updated on  10.02.2018
Formerunknown
Status updated on  01.09.2017
Most recent event   Tooltip30.09.2022Application deemed to be withdrawnpublished on 02.11.2022  [2022/44]
Applicant(s)For all designated states
TCR2 Therapeutics Inc.
100 Binney Street, 7th Floor
Cambridge, Massachusetts 02142 / US
[N/P]
Former [2019/24]For all designated states
TCR2 Therapeutics Inc.
100 Binney Street 7th Floor
Cambridge, Massachusetts 02142 / US
Inventor(s)01 / BAEUERLE, Patrick
450 Kendall Street
Cambridge, Massachusetts 02142 / US
02 / SIECZKIEWICZ, Gregory
450 Kendall Street
Cambridge, Massachusetts 02142 / US
03 / HOFMEISTER, Robert
4 Jason's Lane
Scituate, Massachusetts 02066 / US
 [2019/24]
Representative(s)Kilburn & Strode LLP
Lacon London
84 Theobalds Road
Holborn
London WC1X 8NL / GB
[N/P]
Former [2019/24]Cornish, Kristina Victoria Joy, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
Application number, filing date17754238.802.08.2017
[2019/24]
WO2017US45159
Priority number, dateUS201662370189P02.08.2016         Original published format: US 201662370189 P
[2019/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018026953
Date:08.02.2018
Language:EN
[2018/06]
Type: A1 Application with search report 
No.:EP3494138
Date:12.06.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 08.02.2018 takes the place of the publication of the European patent application.
[2019/24]
Search report(s)International search report - published on:EP08.02.2018
ClassificationIPC:C07K16/28, C07K14/705
[2019/24]
CPC:
C07K14/705 (EP,US); C07K14/7051 (EP,US); A61K35/17 (US);
A61K39/4611 (EP); A61K39/4631 (EP); A61K39/4644 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/04 (EP);
A61P43/00 (EP); C07K14/70521 (US); C07K16/2878 (EP,US);
A61K2035/124 (US); A61K2039/505 (EP,US); A61K2039/5156 (US);
A61K2239/31 (EP); A61K2239/38 (EP); C07K2317/24 (US);
C07K2317/569 (US); C07K2317/622 (EP,US); C07K2317/73 (EP,US);
C07K2319/02 (US); C07K2319/03 (EP,US); C07K2319/33 (EP,US);
C07K2319/74 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/24]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN FÜR TCR-PROGRAMMIERUNG MIT FUSIONSPROTEINEN[2019/24]
English:COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS[2019/24]
French:COMPOSITIONS ET MÉTHODES DE REPROGRAMMATION DE TCR EN UTILISANT DES PROTÉINES DE FUSION[2019/24]
Entry into regional phase08.02.2019National basic fee paid 
08.02.2019Designation fee(s) paid 
08.02.2019Examination fee paid 
Examination procedure08.02.2019Examination requested  [2019/24]
08.02.2019Date on which the examining division has become responsible
23.09.2019Amendment by applicant (claims and/or description)
20.04.2020Despatch of a communication from the examining division (Time limit: M06)
23.10.2020Reply to a communication from the examining division
24.01.2022Despatch of a communication from the examining division (Time limit: M04)
04.06.2022Application deemed to be withdrawn, date of legal effect  [2022/44]
28.06.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2022/44]
Fees paidRenewal fee
27.08.2019Renewal fee patent year 03
27.08.2020Renewal fee patent year 04
27.08.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]WO2015158671  (CELLECTIS [FR]) [X] 1-32,35-51,56-64,67-110 * p. 40 li. 29-31, p. 41 li. 19-23, p. 6 li. 11-12, p. 6 li. 25-26, p. 51 li. 3-8, p. 9 li. 29-30, p. 56 li. 31, p. 53 li. 12-14, p. 47 li. 13-15, p. 45 li. 21-24, p. 6 li. 7-8, p. 24 li. 26-28, p. 25 li. 19-20, p. 17 li. 27-28, p. 25 li. 20-24, p. 7 li. 21-30, p. 23 li. 16-21, p. 9 li. 3-14, p. 80 li. 11-14, p. 45 li. 17-30, p. 51 li. 13-18, p. 71 li. 32-p. 72 li. 4, p. 74 li. 17-27, p. 45 li. 17-30, p. 44 li. 14-28 * [I] 34,52-55,65,66;
 [XI]WO2016014789  (BLUEBIRD BIO INC [US]) [X] 1-32,35-51,56-64,67-110 * p. 30 li. 10-p. 31 li. 18, p. 3 li. 25-28, p. 27 li. 25-29, p. 28 li. 28-32, p. 29 li. 7-11, p. 2 li. 27, p. 13 li. 5-6, p. 16 li. 24-27, p. 3 li. 1-6, p. 21 li. 7-12, p. 19 li. 25-31, p. 24 li. 28-p. 25 li. 2, p. 4 li. 3-8, p. 29 li. 20-32, p. 30 li. 12, p. 31 li. 7, p. 25 li. 4-6, p. 25 li. 30-p. 26 li. 12, p. 7 li. 5-8, p. 49 li. 17-23, p. 40 li. 3-6, p. 52 li. 24-26, p. 45 li. 7-10, p. 33 li. 1-4, p. 2 li. 15-16, p. 6 li. 25, p. 8 li. 5-8, p. 66 li. 17-18, p. 8 li. 11-13, p. 8 li. 22-p. 9 li. 5, p. 79 li. 30-p. 80 li. 11, p. 73 li. 17-20, p. 76 li. 17-27;; claims 1-3, 10, 15, 49, 68-69, 71, 76-77 * [I] 34,52-55,65,66;
 [E]WO2017173256  (KITE PHARMA INC [US]) [E] 1-110 * the whole document *;
 [Y]  - XIUFENG WU ET AL, "Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies", MABS, US, (20150122), vol. 7, no. 2, doi:10.1080/19420862.2015.1007826, ISSN 1942-0862, pages 364 - 376, XP055417077 [Y] 1-110 * the whole document *

DOI:   http://dx.doi.org/10.1080/19420862.2015.1007826
 [Y]  - JENNIFER D. STONE ET AL, "A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control", CANCER IMMUNOLOGY, IMMUNOTHERAPY, Berlin/Heidelberg, (20140801), vol. 63, no. 11, doi:10.1007/s00262-014-1586-z, ISSN 0340-7004, pages 1163 - 1176, XP055364633 [Y] 1-110 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00262-014-1586-z
 [Y]  - ARVIND CHHABRA, "TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations", THE SCIENTIFIC WORLD JOURNAL, (20110101), vol. 11, doi:10.1100/tsw.2011.10, pages 121 - 129, XP055416645 [Y] 1-110 * the whole document *

DOI:   http://dx.doi.org/10.1100/tsw.2011.10
 [Y]  - CARPENTER R O ET AL, "B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 8, doi:10.1158/1078-0432.CCR-12-2422, ISSN 1078-0432, (20130415), pages 2048 - 2060, (20130123), XP002727959 [Y] 1-110 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-12-2422
by applicantEP0239400
 US4816567
 WO9109967
 EP0519596
 US5199942
 US5225539
 WO9317105
 EP0592106
 US5350674
 US5399346
 US5530101
 US5565332
 US5580859
 US5585089
 US5585362
 US5589466
 US5766886
 US5858358
 US5883223
 US6120766
 WO0129058
 US6326193
 US6331415
 WO0196584
 US6352694
 US6407213
 US6534055
 US6548640
 US6692964
 US6797514
 US2005042664
 US2005048617
 US6867041
 US6887466
 US2005100543
 US6905680
 US6905681
 US6905874
 US2005175606
 WO2006020258
 US7067318
 US7144575
 US7172869
 US7175843
 WO2007024715
 US7232566
 US7572631
 US7695936
 WO2012138475
 WO2013126712
 US8697359
 US9393257
    - MILONE et al., Mol. Ther., (20090000), vol. 17, no. 8, pages 1453 - 1464
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - REICHMANN et al., Nature, (19880000), vol. 332, pages 323 - 329
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596
    - BATZER et al., Nucleic Acid Res., (19910000), vol. 19, page 5081
    - OHTSUKA et al., J. Biol. Chem., (19850000), vol. 260, pages 2605 - 2608
    - ROSSOLINI et al., Mol. Cell. Probes, (19940000), vol. 8, pages 91 - 98
    - PADLAN, Molecular Immunology, (19910000), vol. 28, no. 4/5, pages 489 - 498
    - STUDNICKA et al., Protein Engineering, (19940000), vol. 7, no. 6, pages 805 - 814
    - ROGUSKA et al., PNAS, (19940000), vol. 91, pages 969 - 973
    - TAN et al., J. Immunol., (20020000), vol. 169, pages 1119 - 25
    - CALDAS et al., Protein Eng., (20000000), vol. 13, no. 5, pages 353 - 60
    - MOREA et al., Methods, (20000000), vol. 20, no. 3, pages 267 - 79
    - BACA et al., J. Biol. Chem., (19970000), vol. 272, no. 16, pages 10678 - 84
    - ROGUSKA et al., Protein Eng., (19960000), vol. 9, no. 10, pages 895 - 904
    - COUTO et al., Cancer Res., (19950000), vol. 55, no. 23, pages 5973s - 5977s
    - COUTO et al., Cancer Res., (19950000), vol. 55, no. 8, pages 1717 - 22
    - SANDHU J S, Gene, vol. 150, no. 2, pages 409 - 10
    - PEDERSEN et al., J. Mol. Biol., (19940000), vol. 235, no. 3, pages 959 - 73
    - RIECHMANN et al., Nature, (19880000), vol. 332, page 323
    - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327
    - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
    - SIMS et al., J. Immunol., (19930000), vol. 151, page 2296
    - CHOTHIA et al., J. Mol. Biol., (19870000), vol. 196, page 901
    - NICHOLSON et al., Mol. Immun., (19970000), vol. 34, no. 16-17, pages 1157 - 1165
    - CARTER et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, page 4285
    - PRESTA et al., J. Immunol., (19930000), vol. 151, page 2623
    - LANZAVECCHIA et al., Eur. J. Immunol., (19870000), vol. 17, page 105
    - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426
    - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
    - HOLLINGER et al., Proc Natl Acad. Sci. U.S.A., (19930000), vol. 90, pages 6444 - 6448
    - SMITH; WATERMAN, Adv. Appl. Math., (19700000), vol. 2, page 482c
    - NEEDLEMAN; WUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443
    - PEARSON; LIPMAN, Proc. Nat'l. Acad. Sci. USA, (19880000), vol. 85, page 2444
    - ALTSCHUL et al., Nuc. Acids Res., (19770000), vol. 25, pages 3389 - 3402
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - SONG et al., Blood., (20120000), vol. 119, no. 3, pages 696 - 706
    - AGATA et al., Int. Immunol, (19960000), vol. 8, pages 765 - 75
    - FREEMAN et al., J Exp Med, (20000000), vol. 192, pages 1027 - 34
    - LATCHMAN et al., Nat Immunol, (20010000), vol. 2, pages 261 - 8
    - CARTER et al., Eur J Immunol, (20020000), vol. 32, pages 634 - 43
    - DONG et al., Mol Med, (20030000), vol. 81, pages 281 - 7
    - BLANK et al., Cancer Immunol. Immunother, (20050000), vol. 54, pages 307 - 314
    - KONISHI et al., Clin Cancer Res, (20040000), vol. 10, page 5094
    - SCHENBORN; MIERENDORF, Nuc Acids Res., (19850000), vol. 13, pages 6223 - 36
    - NACHEVA; BERZAL-HERRANZ, Eur. J. Biochem., (20030000), vol. 270, pages 1485 - 65
    - COUGOT et al., Trends in Biochem. Sci., (20010000), vol. 29, pages 436 - 444
    - STEPINSKI et al., RNA, (20010000), vol. 7, pages 1468 - 95
    - ELANGO et al., Biochim. Biophys. Res. Commun., (20050000), vol. 330, pages 958 - 966
    - NISHIKAWA et al., Hum Gene Ther., (20010000), vol. 12, no. 8, pages 861 - 70
    - URNOV et al., Nat. Rev. Genetics, (20100000), vol. 1, pages 636 - 646
    - SANDER; JOUNG, Nat. Biotech., (20140000), vol. 32, pages 347 - 55
    - JUNE et al., Nature Reviews Immunol., (20090000), vol. 9.10, pages 704 - 716
    - SAMBROOK et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, (20120000), vol. 1-4
    - UI-TEI et al., FEBS Letters, (20000000), vol. 479, pages 79 - 82
    - GHOSH et al., Glycobiology, (19910000), vol. 5, pages 505 - 10
    - BERG et al., Transplant Proc., (19980000), vol. 30, no. 8, pages 3975 - 3977
    - HAANEN et al., J. Exp. Med., (19990000), vol. 190, no. 9, page 13191328
    - GARLAND et al., J. Immunol. Meth., (19990000), vol. 227, no. 1-2, pages 53 - 63
    - MILONE et al., Molecular Therapy, (20090000), vol. 17, no. 8, pages 1453 - 1464
    - BARRETT et al., Human Gene Therapy, (20110000), vol. 22, pages 1575 - 1586
    - IZUMOTO et al., J Neurosurg, (20080000), vol. 108, pages 963 - 971
    - ROSENBERG et al., New Eng. J. of Med., (19880000), vol. 319, page 1676
    - BARRETINA et al., Nature, (20120000), vol. 483, page 603
    - MORTON et al., Nat. Procol., (20070000), vol. 2, page 247
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.